{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:19:50Z","timestamp":1792876790039,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100006093","name":"PCORI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"name":"REACHnet"},{"name":"PCORnet"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K01 HL141690"],"award-info":[{"award-number":["K01 HL141690"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["CDRN-1501-26692"],"award-info":[{"award-number":["CDRN-1501-26692"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["RI-FLORIDA-01-PS1"],"award-info":[{"award-number":["RI-FLORIDA-01-PS1"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Florida Department of Health\u2019s James and Esther King Biomedical Research Program","award":["4KB16"],"award-info":[{"award-number":["4KB16"]}]},{"DOI":"10.13039\/100018488","name":"University of Florida Clinical and Translational Science Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"NIH National Center for Advancing Translational Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012729","name":"Clinical and Translational Science Collaborative of Cleveland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012729","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH roadmap for Medical Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Apparent treatment-resistant hypertension (aTRH) is defined as uncontrolled blood pressure (BP) despite using \u22653 antihypertensive classes or controlled BP while using \u22654 antihypertensive classes. Patients with aTRH have a higher risk for adverse cardiovascular outcomes compared with patients with controlled hypertension (HTN). Although there have been prior reports on the prevalence, characteristics, and predictors of aTRH, these have been broadly derived from smaller datasets, randomized controlled trials, or closed healthcare systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We extracted patients with HTN defined by ICD-9 and ICD-10 codes during 1\/1\/2015\u201312\/31\/2018, from 2 large electronic health record databases: the OneFlorida Data Trust (n = 223,384) and Research Action for Health Network (REACHnet) (n = 175,229). We applied our previously validated aTRH and stable controlled HTN computable phenotype algorithms and performed univariate and multivariate analyses to identify the prevalence, characteristics, and predictors of aTRH in these populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The prevalence of aTRH among patients with HTN in OneFlorida (16.7%) and REACHnet (11.3%) was similar to prior reports. Both populations had a significantly higher proportion of Black patients with aTRH compared with those with stable controlled HTN. aTRH in both populations shared similar significant predictors, including Black race, diabetes, heart failure, chronic kidney disease, cardiomegaly, and higher body mass index. In both populations, aTRH was significantly associated with similar comorbidities, when compared with stable controlled HTN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>In 2 large, diverse real-world populations, we observed similar comorbidities and predictors of aTRH as prior studies. In the future, these results may be used to improve healthcare professionals\u2019 understanding of aTRH predictors and associated comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajh\/hpad084","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T17:40:07Z","timestamp":1694540407000},"page":"60-68","source":"Crossref","is-referenced-by-count":16,"title":["Characteristics and Predictors of Apparent Treatment-Resistant Hypertension in Real-World Populations Using Electronic Health Record-Based Data"],"prefix":"10.1093","volume":"37","author":[{"given":"Eissa","family":"Jafari","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida , Gainesville, Florida , USA"},{"name":"Department of Pharmacy Practice, College of Pharmacy, Jazan University , Jazan , Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda M","family":"Cooper-DeHoff","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida , Gainesville, Florida , USA"},{"name":"Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida , Gainesville, Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark B","family":"Effron","sequence":"additional","affiliation":[{"name":"John Ochsner Heart and Vascular Institute, The University of Queensland Ochsner Clinical School , New Orleans, Louisiana , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R","family":"Hogan","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida , Gainesville, Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitrin W","family":"McDonough","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida , Gainesville, Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"2023121606065063600_CIT0001","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2023121606065063600_CIT0002","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics\u20142023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"2023121606065063600_CIT0003","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1097\/HJH.0000000000000379","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels\u2014overview and meta-analyses of randomized trials","volume":"32","author":"Thomopoulos","year":"2014","journal-title":"J Hypertens"},{"key":"2023121606065063600_CIT0004","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/jhh.2013.140","article-title":"Apparent and true resistant hypertension: definition, prevalence and outcomes","volume":"28","author":"Judd","year":"2014","journal-title":"J Hum Hypertens"},{"key":"2023121606065063600_CIT0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","article-title":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients","volume":"105","author":"Noubiap","year":"2019","journal-title":"Heart"},{"key":"2023121606065063600_CIT0006","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/HJH.0000000000000051","article-title":"Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension","volume":"32","author":"Smith","year":"2014","journal-title":"J Hypertens"},{"key":"2023121606065063600_CIT0007","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1097\/HJH.0b013e32834a8a42","article-title":"Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk","volume":"29","author":"Gupta","year":"2011","journal-title":"J Hypertens"},{"key":"2023121606065063600_CIT0008","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.mayocp.2013.06.017","article-title":"Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system","volume":"88","author":"Sim","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"2023121606065063600_CIT0009","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","article-title":"Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"4","author":"Cushman","year":"2002","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2023121606065063600_CIT0010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/HYPERTENSIONAHA.115.06487","article-title":"Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the Chronic Renal Insufficiency Cohort Study","volume":"67","author":"Thomas","year":"2016","journal-title":"Hypertension"},{"key":"2023121606065063600_CIT0011","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/HYPERTENSIONAHA.114.03850","article-title":"Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"64","author":"Muntner","year":"2014","journal-title":"Hypertension"},{"key":"2023121606065063600_CIT0012","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jash.2014.03.003","article-title":"Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality","volume":"8","author":"Irvin","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"2023121606065063600_CIT0013","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ki.2015.142","article-title":"Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension","volume":"88","author":"Sim","year":"2015","journal-title":"Kidney Int"},{"key":"2023121606065063600_CIT0014","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamainternmed.2017.6015","article-title":"Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis","volume":"178","author":"Brunstrom","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2023121606065063600_CIT0015","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jash.2016.08.008","article-title":"Prevalence of treatment-resistant hypertension and important associated factors\u2014results from the Swedish Primary Care Cardiovascular Database","volume":"10","author":"Holmqvist","year":"2016","journal-title":"J Am Soc Hypertens"},{"key":"2023121606065063600_CIT0016","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/jch.12410","article-title":"Resistant hypertension and associated comorbidities in a veterans affairs population","volume":"16","author":"Acharya","year":"2014","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2023121606065063600_CIT0017","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/jch.12773","article-title":"Blood pressure control provides less cardiovascular protection in adults with than without apparent treatment-resistant hypertension","volume":"18","author":"Egan","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2023121606065063600_CIT0018","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.amjmed.2013.07.038","article-title":"Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease","volume":"127","author":"Bangalore","year":"2014","journal-title":"Am J Med"},{"key":"2023121606065063600_CIT0019","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/pds.5095","article-title":"Optimizing identification of resistant hypertension: computable phenotype development and validation","volume":"29","author":"McDonough","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2023121606065063600_CIT0020","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/jamia\/ocab221","article-title":"The OneFlorida Data Trust: a centralized, translational research data infrastructure of statewide scope","volume":"29","author":"Hogan","year":"2022","journal-title":"J Am Med Inform Assoc"},{"key":"2023121606065063600_CIT0021","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12885-021-08067-1","article-title":"Understanding the patient journey to diagnosis of lung cancer","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Cancer"},{"key":"2023121606065063600_CIT0022","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/amiajnl-2014-002747","article-title":"Launching PCORnet, a national patient-centered clinical research network","volume":"21","author":"Fleurence","year":"2014","journal-title":"J Am Med Inform Assoc"},{"key":"2023121606065063600_CIT0023","doi-asserted-by":"crossref","first-page":"e14777","DOI":"10.2196\/14777","article-title":"Optimizing antihypertensive medication classification in electronic health record-based data: classification system development and methodological comparison","volume":"8","author":"McDonough","year":"2020","journal-title":"JMIR Med Inform"},{"key":"2023121606065063600_CIT0024","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jama.2021.13304","article-title":"Updated guidance on the reporting of race and ethnicity in medical and science journals","volume":"326","author":"Flanagin","year":"2021","journal-title":"JAMA"},{"key":"2023121606065063600_CIT0025","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1161\/HYPERTENSIONAHA.121.17570","article-title":"Racial\/ethnic disparities in hypertension prevalence, awareness, treatment, and control in the United States, 2013 to 2018","volume":"78","author":"Aggarwal","year":"2021","journal-title":"Hypertension"},{"key":"2023121606065063600_CIT0026","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1097\/HJH.0000000000002419","article-title":"Apparent treatment-resistant hypertension: characteristics and prevalence in a real-world environment of an integrated health system","volume":"38","author":"An","year":"2020","journal-title":"J Hypertens"},{"key":"2023121606065063600_CIT0027","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/HYPERTENSIONAHA.118.12191","article-title":"Prevalence of apparent treatment-resistant hypertension in the United States","volume":"73","author":"Carey","year":"2019","journal-title":"Hypertension"},{"key":"2023121606065063600_CIT0028","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/CIRCULATIONAHA.111.030189","article-title":"Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008","volume":"124","author":"Egan","year":"2011","journal-title":"Circulation"},{"key":"2023121606065063600_CIT0029","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1161\/HYPERTENSIONAHA.111.170308","article-title":"Prevalence of resistant hypertension in the United States, 2003\u20132008","volume":"57","author":"Persell","year":"2011","journal-title":"Hypertension"},{"key":"2023121606065063600_CIT0030","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3109\/08037051.2011.622983","article-title":"Abnormalities of vascular function in resistant hypertension","volume":"21","author":"de La Sierra","year":"2012","journal-title":"Blood Press"},{"key":"2023121606065063600_CIT0031","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1751-7176.2012.00653.x","article-title":"Relationship of resistant hypertension and treatment outcomes with total arterial compliance in a predominantly African American hypertensive cohort","volume":"14","author":"Bakhtar","year":"2012","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2023121606065063600_CIT0032","doi-asserted-by":"crossref","first-page":"100044","DOI":"10.1016\/j.ijchy.2020.100044","article-title":"Prevalence and control rates of hypertension in the USA: 2017\u20132018","volume":"6","author":"Chobufo","year":"2020","journal-title":"Int J Cardiol Hypertens"},{"key":"2023121606065063600_CIT0033","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/jhh.2013.32","article-title":"Clinical characteristics of patients with resistant hypertension: the RESIST-POL study","volume":"27","author":"Florczak","year":"2013","journal-title":"J Hum Hypertens"},{"key":"2023121606065063600_CIT0034","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1161\/HYPERTENSIONAHA.111.179788","article-title":"Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension","volume":"58","author":"Pedrosa","year":"2011","journal-title":"Hypertension"},{"key":"2023121606065063600_CIT0035","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/HYPERTENSIONAHA.113.01448","article-title":"Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network","volume":"62","author":"Egan","year":"2013","journal-title":"Hypertension"},{"key":"2023121606065063600_CIT0036","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1161\/HYPERTENSIONAHA.116.08128","article-title":"Trends in antihypertensive medication use among US patients with resistant hypertension, 2008 to 2014","volume":"68","author":"Hwang","year":"2016","journal-title":"Hypertension"},{"key":"2023121606065063600_CIT0037","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"2023121606065063600_CIT0038","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"2023121606065063600_CIT0039","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1053\/j.ackd.2014.11.006","article-title":"Sodium retention and volume expansion in nephrotic syndrome: implications for hypertension","volume":"22","author":"Ray","year":"2015","journal-title":"Adv Chronic Kidney Dis"},{"key":"2023121606065063600_CIT0040","doi-asserted-by":"crossref","first-page":"E773","DOI":"10.1503\/cmaj.161486","article-title":"Primary aldosteronism: a common cause of resistant hypertension","volume":"189","author":"Kline","year":"2017","journal-title":"CMAJ"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpad084\/51821648\/hpad084.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/37\/1\/60\/54533473\/hpad084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/37\/1\/60\/54533473\/hpad084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T01:07:47Z","timestamp":1702688867000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/37\/1\/60\/7274369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,9,15]]},"published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpad084","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.04.28.23289293","asserted-by":"object"}]},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,9,15]]}}}